Schedule 13D ownership disclosure
ACRIVON THERAPEUTICS INC
Common Stock, par value $0.001 per share · CUSIP: 004890109
Event date: 2026-03-19
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- RA Capital Management, L.P.Reported CIK 0001346824
Shares: 8,396,018.00 · Class: 21.6%
- Peter KolchinskyReported CIK 0001384859
Shares: 8,396,018.00 · Class: 21.6%
- Rajeev ShahReported CIK 0001619841
Shares: 8,396,018.00 · Class: 21.6%
- RA Capital Healthcare Fund, L.P.Reported CIK 0001315082
Shares: 7,914,206.00 · Class: 20.4%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001346824-26-000081
- Form type
- SCHEDULE 13D/A
- Filer
- Acrivon Therapeutics, Inc.
- CIK
- CIK 1781174
- Filed
- Mar 23, 2026
- Reporting period
- Mar 19, 2026
- Description
- Schedule 13D beneficial ownership